Literature DB >> 25494653

Revisiting peptide identification by high-accuracy mass spectrometry: problems associated with the use of narrow mass precursor windows.

Elena Bonzon-Kulichenko1, Fernando Garcia-Marques, Marco Trevisan-Herraz, Jesús Vázquez.   

Abstract

Peptide identification is increasingly achieved through database searches in which mass precursor tolerance is set in the ppm range. This trend is driven by the high resolution and accuracy of modern mass spectrometers and the belief that the quality of peptide identification is fully controlled by estimating the false discovery rate (FDR) using the decoy-target approach. However, narrowing mass tolerance decreases the number of sequence candidates, and several authors have raised concerns that these search conditions can introduce inaccuracies. Here, we demonstrate that when scores that only depend on one sequence candidate are used, decoy-based estimates of the number of false positive identifications are accurate even with an average number of candidates of just 200, to the point that remarkably accurate FDR predictions can be made in completely different search conditions. However, when scores that are constructed taking information from additional sequence candidates are used together with low precursor mass tolerances, the proportion of peptides incorrectly identified may become significantly higher than the FDR estimated by the target-decoy approach. Our results suggest that with this kind of score the high mass accuracy of modern mass spectrometers should be exploited by using wide mass windows followed by postscoring mass filtering algorithms.

Keywords:  False discovery rate; high-resolution mass spectrometry; peptide identification

Mesh:

Substances:

Year:  2014        PMID: 25494653     DOI: 10.1021/pr5007284

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  28 in total

1.  Muscle molecular adaptations to endurance exercise training are conditioned by glycogen availability: a proteomics-based analysis in the McArdle mouse model.

Authors:  Carmen Fiuza-Luces; Alejandro Santos-Lozano; Francisco Llavero; Rocío Campo; Gisela Nogales-Gadea; Jorge Díez-Bermejo; Carlos Baladrón; África González-Murillo; Joaquín Arenas; Miguel A Martín; Antoni L Andreu; Tomàs Pinós; Beatriz G Gálvez; Juan A López; Jesús Vázquez; José L Zugaza; Alejandro Lucia
Journal:  J Physiol       Date:  2018-02-14       Impact factor: 5.182

2.  A Novel Systems-Biology Algorithm for the Analysis of Coordinated Protein Responses Using Quantitative Proteomics.

Authors:  Fernando García-Marqués; Marco Trevisan-Herraz; Sara Martínez-Martínez; Emilio Camafeita; Inmaculada Jorge; Juan Antonio Lopez; Nerea Méndez-Barbero; Simón Méndez-Ferrer; Miguel Angel Del Pozo; Borja Ibáñez; Vicente Andrés; Francisco Sánchez-Madrid; Juan Miguel Redondo; Elena Bonzon-Kulichenko; Jesús Vázquez
Journal:  Mol Cell Proteomics       Date:  2016-02-18       Impact factor: 5.911

3.  NOTCH Activation Promotes Valve Formation by Regulating the Endocardial Secretome.

Authors:  Rebeca Torregrosa-Carrión; Luis Luna-Zurita; Fernando García-Marqués; Gaetano D'Amato; Rebeca Piñeiro-Sabarís; Elena Bonzón-Kulichenko; Jesús Vázquez; José Luis de la Pompa
Journal:  Mol Cell Proteomics       Date:  2019-06-27       Impact factor: 5.911

4.  Aortic disease in Marfan syndrome is caused by overactivation of sGC-PRKG signaling by NO.

Authors:  Andrea de la Fuente-Alonso; Marta Toral; Alvaro Alfayate; María Jesús Ruiz-Rodríguez; Elena Bonzón-Kulichenko; Gisela Teixido-Tura; Sara Martínez-Martínez; María José Méndez-Olivares; Dolores López-Maderuelo; Ileana González-Valdés; Eusebio Garcia-Izquierdo; Susana Mingo; Carlos E Martín; Laura Muiño-Mosquera; Julie De Backer; J Francisco Nistal; Alberto Forteza; Arturo Evangelista; Jesús Vázquez; Miguel R Campanero; Juan Miguel Redondo
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

5.  Proteomic footprint of myocardial ischemia/reperfusion injury: Longitudinal study of the at-risk and remote regions in the pig model.

Authors:  Aleksandra Binek; Rodrigo Fernández-Jiménez; Inmaculada Jorge; Emilio Camafeita; Juan Antonio López; Navratan Bagwan; Carlos Galán-Arriola; Andres Pun; Jaume Agüero; Valentin Fuster; Borja Ibanez; Jesús Vázquez
Journal:  Sci Rep       Date:  2017-09-27       Impact factor: 4.379

6.  Immune system deregulation in hypertensive patients chronically RAS suppressed developing albuminuria.

Authors:  Marta Martin-Lorenzo; Laura Gonzalez-Calero; Paula J Martinez; Montserrat Baldan-Martin; Juan Antonio Lopez; Gema Ruiz-Hurtado; Fernando de la Cuesta; Julián Segura; Jesús Vazquez; Fernando Vivanco; Maria G Barderas; Luis M Ruilope; Gloria Alvarez-Llamas
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

7.  Quantitative proteomics reveals Piccolo as a candidate serological correlate of recovery from Guillain-Barré syndrome.

Authors:  Lourdes Mateos-Hernández; Margarita Villar; Ernesto Doncel-Pérez; Marco Trevisan-Herraz; Ángel García-Forcada; Francisco Romero Ganuza; Jesús Vázquez; José de la Fuente
Journal:  Oncotarget       Date:  2016-11-15

8.  The potential clinical impact of the release of two drafts of the human proteome.

Authors:  Iakes Ezkurdia; Enrique Calvo; Angela Del Pozo; Jesús Vázquez; Alfonso Valencia; Michael L Tress
Journal:  Expert Rev Proteomics       Date:  2015-10-23       Impact factor: 3.940

9.  Urinary exosomes reveal protein signatures in hypertensive patients with albuminuria.

Authors:  Laura Gonzalez-Calero; Paula J Martínez; Marta Martin-Lorenzo; Montserrat Baldan-Martin; Gema Ruiz-Hurtado; Fernando de la Cuesta; Eva Calvo; Julian Segura; Juan Antonio Lopez; Jesús Vázquez; Maria G Barderas; Luis M Ruilope; Fernando Vivanco; Gloria Alvarez-Llamas
Journal:  Oncotarget       Date:  2017-07-04

10.  Cleaning out the Litterbox of Proteomic Scientists' Favorite Pet: Optimized Data Analysis Avoiding Trypsin Artifacts.

Authors:  Matthias Schittmayer; Katarina Fritz; Laura Liesinger; Johannes Griss; Ruth Birner-Gruenberger
Journal:  J Proteome Res       Date:  2016-03-22       Impact factor: 5.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.